Journal article icon

Journal article

Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer.

Abstract:

Vandetanib is a multi-targeted receptor tyrosine kinase inhibitor that is in clinical development for the treatment of solid tumours. This preclinical study examined the inhibition of two key signalling pathways (VEGFR-2, EGFR) at drug concentrations similar to those achieved in the clinic, and their contribution to direct and indirect antitumour effects of vandetanib. For in vitro studies, receptor phosphorylation was assessed by Western blotting and ELISA, cell proliferation was assessed us...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.3892/ijo.2011.1022

Authors


Marshall, GB More by this author
Expand authors...
Journal:
International journal of oncology
Volume:
39
Issue:
1
Pages:
271-278
Publication date:
2011-07-05
DOI:
EISSN:
1791-2423
ISSN:
1019-6439
URN:
uuid:7980ee12-d7a0-4488-bc45-185942180fb0
Source identifiers:
149913
Local pid:
pubs:149913

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP